登录 注册 会员服务 联系我们

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

  • Published:2020-09-28 Issue:2 Volume:39 Page:509-515
  • ISSN:0167-6997
  • Container-title:Investigational New Drugs
  • language:en
  • Short-container-title:Invest New Drugs

Author:

Yam Clinton,Rauch Gaiane M.,Rahman Tanbin,Karuturi Meghan,Ravenberg Elizabeth,White Jason,Clayborn Alyson,McCarthy Pamela,Abouharb Sausan,Lim Bora,Litton Jennifer K.,Ramirez David L.,Saleem Sadia,Stec James,Symmans W. Fraser,Huo Lei,Damodaran Senthil,Sun Ryan,Moulder Stacy L.

Funder

National Comprehensive Cancer Network

National Institutes of Health

University of Texas MD Anderson Cancer Center

The Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology

Susan Papizan Dolan Fellowship in Breast Oncology

Conquer Cancer Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Reference27 articles.

1. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, Jordan MA (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9(10):2689–2699. https://doi.org/10.1158/1535-7163.MCT-10-0644

2. Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM (2015) IMGN853, a Folate Receptor-alpha (FRalpha)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRalpha-Expressing Tumors. Mol Cancer Ther 14(7):1605–1613. https://doi.org/10.1158/1535-7163.MCT-14-1095

3. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21(1):84–92. https://doi.org/10.1021/bc900315y

4. Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ (2017) Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 123(16):3080–3087. https://doi.org/10.1002/cncr.30736

5. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's surveillance, epidemiology, and end results database. Cancer 110(4):876–884. https://doi.org/10.1002/cncr.22836

Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3